Back to results
US 12,767,988 B2Granted
Cancer biomarkers
AssigneeMyriad Genetics, Inc.
InventorsSteven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Life of this patent
Estimating the term…
Abstract
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Claims19
A method of analyzing a tumor sample, comprising:
- (a) extracting RNA from a tumor sample from a patient with prostate, bladder, brain, breast, or lung cancer;
- (b) converting the extracting RNA to cDNA;
- and
- (c) assaying the cDNA to determine an expression level for a set of marker genes consisting of at least 10 and up to all of ASFIB, ASPM, BIRC5, BUB1B, C19orj24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXMI, KIAA0101, KIF11, KIF20A, KIF4A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1, and TOP2A, wherein the assaying comprises:
- (i) amplifying the cDNA of the set of marker genes;
- and
- (ii) detecting the expression levels of the set of marker genes by measuring the level of amplified cDNA;
- wherein expression levels of no more than 50 genes are detected.
5 more elements
A method of analyzing a tumor sample, consisting essentially of:
- (a) extracting RNA from a tumor sample from a patient with prostate, bladder, brain, breast, or lung cancer;
- (b) converting the extracting RNA to cDNA;
- and
- (c) assaying the cDNA to determine an expression level for a set of marker genes comprising 10-32 genes selected from ASF1B, ASPM, BIRC5, BUB1B, C19orj24, CDC2,CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXMI, KIAA0101, KIF11, KIF20A, KIF4A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1, and TOP2A, wherein the assaying comprises:
- (i) amplifying the cDNA of the set of marker genes;
- and
- (ii) detecting the expression levels of the set of marker genes by measuring the level of amplified cDNA;
- wherein expression levels of no more than 50 genes are detected.
5 more elements
A method of analyzing a tumor sample, consisting of:
- assaying the cDNA that was converted from RNA extracted from a tumor sample from a patient with prostate, bladder, brain, breast, or lung cancer to determine an expression level for a set of marker genes consisting of 10-32 genes selected from ASF1B, ASPM, BIRC5, BUBIB, C19orj24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, KIF4A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1, and TOP2A, wherein the assaying comprises:
- (i) amplifying the cDNA of the set of marker genes;
- and
- (ii) detecting the expression levels of the set of marker genes by measuring the level of amplified cDNA;
- and
- optionally wherein the expression of the set of marker genes is normalized to the expression of one or more housekeeping genes.
3 more elements
Dependencies are inferred from the claim text.